Perfusion-guided endovascular super-selective intra-arterial infusion for treatment of malignant brain tumors

J Neurointerv Surg. 2022 Jun;14(6):533-538. doi: 10.1136/neurintsurg-2021-018190. Epub 2021 Nov 25.

Abstract

Background: Survival for glioblastoma remains very poor despite decades of research, with a 5-year survival of only 5%. The technological improvements that have revolutionized treatment of ischemic stroke and brain aneurysms have great potential in providing more precise and selective delivery of cancer therapeutic agents to brain tumors.

Methods: We describe for the first time the use of perfusion guidance to enhance the precision of endovascular super-selective intra-arterial (ESIA) infusions of mesenchymal stem cells loaded with Delta-24 (MSC-D24) in the treatment of glioblastoma (NCT03896568).

Results: MRI imaging, which best defines the location of the tumor, is co-registered and fused with the patient's position using cone beam CT, resulting in optimal vessel selection and confirmation of targeted delivery through volumetric perfusion imaging.

Conclusions: This technique of perfusion guided-ESIA injections (PG-ESIA) enhances our ability to perform targeted super-selective delivery of therapeutic agents for brain tumors.

Keywords: angiography; brain; intervention; neoplasm; tumor.

Publication types

  • Clinical Trial

MeSH terms

  • Brain Neoplasms* / diagnostic imaging
  • Brain Neoplasms* / drug therapy
  • Glioblastoma* / drug therapy
  • Glioblastoma* / therapy
  • Humans
  • Infusions, Intra-Arterial / methods
  • Injections, Intra-Arterial
  • Perfusion

Associated data

  • ClinicalTrials.gov/NCT03896568